Calamos Advisors LLC Lowers Position in Boston Scientific Co. (NYSE:BSX)

Calamos Advisors LLC cut its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,120,564 shares of the medical equipment provider’s stock after selling 4,939 shares during the period. Calamos Advisors LLC’s holdings in Boston Scientific were worth $64,780,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. FMR LLC increased its position in shares of Boston Scientific by 6.8% during the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after purchasing an additional 8,045,263 shares during the last quarter. Vanguard Group Inc. grew its position in Boston Scientific by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after acquiring an additional 1,525,432 shares during the last quarter. Wellington Management Group LLP grew its position in Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock worth $2,221,641,000 after acquiring an additional 2,336,348 shares during the last quarter. Geode Capital Management LLC grew its position in Boston Scientific by 1.9% during the 1st quarter. Geode Capital Management LLC now owns 25,329,129 shares of the medical equipment provider’s stock worth $1,263,857,000 after acquiring an additional 473,888 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Boston Scientific by 7.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 23,393,853 shares of the medical equipment provider’s stock worth $1,082,436,000 after acquiring an additional 1,659,431 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BSX has been the topic of several recent research reports. BTIG Research restated a “buy” rating and set a $64.00 price target on shares of Boston Scientific in a research report on Friday, December 29th. JPMorgan Chase & Co. raised their price target on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Truist Financial raised their price target on Boston Scientific from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Finally, Royal Bank of Canada increased their price objective on Boston Scientific from $70.00 to $78.00 and gave the stock an “outperform” rating in a report on Monday. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $68.50.

Boston Scientific Stock Down 0.8 %

NYSE:BSX traded down $0.54 during trading hours on Thursday, reaching $67.42. 5,946,614 shares of the company traded hands, compared to its average volume of 6,369,346. The business’s 50-day moving average price is $67.17 and its two-hundred day moving average price is $59.68. The stock has a market capitalization of $98.91 billion, a P/E ratio of 63.51, a P/E/G ratio of 2.39 and a beta of 0.78. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $69.21. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.59 billion. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. During the same quarter in the previous year, the business earned $0.45 earnings per share. Analysts predict that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Insider Activity

In other news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold a total of 50,979 shares of company stock valued at $3,418,529 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.